Citation Impact
Citing Papers
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
2001 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Bone marrow-derived mesenchymal stem cells and the tumor microenvironment
2010
Engineering precision nanoparticles for drug delivery
2020 Standout
Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells
2001 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Polymer-drug conjugates: Recent development in clinical oncology
2008
Prodrug Strategies in Anticancer Chemotherapy
2007
Paclitaxel poliglumex for ovarian cancer
2011
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Rapid translocation of nanoparticles from the lung airspaces to the body
2010 StandoutNobel
Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration
2003 Standout
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
1997
Pax7 Is Required for the Specification of Myogenic Satellite Cells
2000 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Biomedical applications of biodegradable polymers
2011 Standout
Evolution of a designed protein assembly encapsulating its own RNA genome
2017 StandoutNatureNobel
Physiologically significant effects of pH and oxygen tension on granulopoiesis
2000
Polymer conjugates as anticancer nanomedicines
2006 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Nanomedicine
2006
Generation of Retroviral Packaging and Producer Cell Lines for Large-Scale Vector Production and Clinical Application: Improved Safety and High Titer
2000
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
2010
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Application of Nanotechnology in Cancer Therapy and Imaging
2008
Advanced materials and processing for drug delivery: The past and the future
2012
Protease-Activated Drug Development
2012
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
2009
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
2012
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
2016 StandoutNobel
Multi-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell
2001 Standout
Beyond tumorigenesis: cancer stem cells in metastasis
2006
Functional activity of murine CD34+and CD34− hematopoietic stem cell populations
1999
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
2014
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
2008 Standout
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Targeted and Equally Distributed Delivery of mRNA to Organs with Pentaerythritol-Based One-Component Ionizable Amphiphilic Janus Dendrimers
2023 StandoutNobel
Stroma-Contact Prevents Loss of Hematopoietic Stem Cell Quality During Ex Vivo Expansion of CD34+ Mobilized Peripheral Blood Stem Cells
1998
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Biology of Hematopoietic Stem Cells and Progenitors: Implications for Clinical Application
2003
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
2014
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Tissue Engineering--Current Challenges and Expanding Opportunities
2002 StandoutScience
Hematopoietic stem cells with controllable tEpoR transgenes have a competitive advantage in bone marrow transplantation
2000 StandoutNobel
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
2011 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
1997
Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen
1993
Polymer–drug conjugation, recent achievements and general strategies
2007
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
2016
Metal–Organic Frameworks in Biomedicine
2011 Standout
Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
2008
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Challenges in the development of magnetic particles for therapeutic applications
2008
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
2002 Standout
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
2016
Nanooncology: The future of cancer diagnosis and therapy
2013
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
2005
Emerging Droplet Microfluidics
2017 Standout
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
Clinical Translation of Nanomedicine
2015
Atomically Precise Clusters of Noble Metals: Emerging Link between Atoms and Nanoparticles
2017 Standout
Works of F. B. Oldham being referenced
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
2008
Highly purified CD34-positive cells reconstitute hematopoiesis.
1996
Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study
2005
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer?drug conjugate
2006
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
2008
Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells
1998
Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors
2005
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
2008
Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors
1996
Phase I Trial of Interferon gamma Retroviral Vector Administered Intratumorally with Multiple Courses in Patients with Metastatic Melanoma
1999
Phase I-II trial of high-dose epirubicin in patients with lymphoma.
1987
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer
1996
Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer
2005
Paclitaxel poliglumex (PPX) and concurrent radiation for treatment of patients with esophageal or gastric cancer: A dose-ranging study
2005
Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2)
2006
Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): Preliminary data
2005
A phase I study of paclitaxel poliglumex (PPX) in combination with cisplatin (CIS) for patients (pts) with advanced cancer
2005
Phase II study of paclitaxel poliglumex (PPX) /carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma
2005